What are you looking for?
Need help finding what you are looking for? Contact Us

PUBLISHER: Mordor Intelligence Pvt Ltd | PRODUCT CODE: 1197221

Cover Image

PUBLISHER: Mordor Intelligence Pvt Ltd | PRODUCT CODE: 1197221

Hyperhidrosis Treatment Market - Growth, Trends, and Forecasts (2023 - 2028)

PAGES: 135 Pages
DELIVERY TIME: 2-3 business days
PDF (Single User License)
USD 4750
PDF (Team License: Up to 7 Users)
USD 5250
PDF (Site License)
USD 6500
PDF (Corporate License)
USD 8750

Add to Cart

The hyperhidrosis treatment market is expected to register a CAGR of 6.2% over the forecast period.

The pandemic has significantly impacted the market. For instance, as per the NCBI study published in January 2021, during the initial phase of the COVID-19 infection, the condition of most of the prolonged cases of hypothermia resulted in fever. Thus, the demand for hyperhidrosis treatment increased initially; however, the market also witnessed an adverse impact. According to the International Hyperhidrosis Society in May 2021, sweat could help prevent the transmission of COVID-19. The organization supports that claim with quotes from experts like dermatologist Adam Friedman of George Washington University, who noted that "Sweat has some inherent antimicrobial activity." Therefore, the market witnessed moderate growth during the initial days of the pandemic. However, with the declining cases of COVID-19, the market has started to gain momentum and is expected to witness an upward trend over the forecast period.

The key factors bolstering the growth of the hyperhidrosis treatment market are the rise in the prevalence of secondary hyperhidrosis conditions and the increase in investments in research and development by the market players. According to the NCBI study published in October 2021, in the United States, the prevalence rate of this disorder was estimated to be around 3.0% of the total population. Emotional, psychological, social, and occupational impairment can all be caused by hyperhidrosis.

Some other factors that could potentially impact the market's growth are the promising pipeline for hyperhidrosis treatment, the growing prevalence of depression and anxiety, growing awareness about hyperhidrosis, and the presence of favorable reimbursement policies. For instance, in October 2021, Brickell Biotech Inc. reported positive topline results from the Phase 3 pivotal Cardigan I and Cardigan II studies, which evaluated sofpironium bromide gel, 15% as a once-daily topical formulation in patients with primary axillary hyperhidrosis. Thus, the increasing burden of hyperhidrosis and treatment advancements are anticipated to bolster the demand for its treatment, thereby boosting the market's growth.

Geographical expansions, product launches, acquisitions, collaborations, mergers, and partnerships by major players to establish a strong presence positively impact the market. For instance, in April 2021, Fortress Biotech, the partner company of Journey Medicals, entered into a definitive agreement to acquire Qbrexza (glycopyrronium) in the United States from Dermira, a wholly-owned subsidiary of Eli Lilly. Thus, owing to these factors, the market studied is expected to witness growth over the forecast period.

However, short-term results of cosmetic and therapeutic procedures are likely to restrain the growth of the hyperhidrosis treatment market over the forecast period.

Hyperhidrosis Treatment Market Trends

Botulin Toxin A is Expected to Hold the Largest Market Share Over the Forecast Period

Botulinum toxin type A is a safe and effective treatment for focal hyperhidrosis that lasts longer than topical treatments and does not require invasive surgical procedures. Botulinum toxin injections are most commonly used to treat axillary hyperhidrosis, but they can also be used to treat palmar and plantar disease. Botulinum toxin's effects last six to nine months on average, and treatment is linked to a high satisfaction rate among patients.

AbbVie Inc. owns BOTOX, which is the most researched botulinum toxin in the world. BOTOX has been approved for the treatment of excessive sweating in the underarms in at least 20 countries. It can also be used off-label to treat sweating in the face, feet, and hands. In April 2021, Aquavit Holdings LLC announced that it acquired an exclusive license to register, market, and commercialize a botulinum toxin (DTX-021) in the United States and Canada. Excessive sweating of the armpits, hands, feet, head, and face (craniofacial) and other relatively small body areas (like under the breasts) can be treated with botulinum toxin A as per the article published by the International Hyperhidrosis Society in October 2020. Botox has been shown to reduce sweating by 82.0% to 87.0% when used to treat excessive sweating under the arms. The effects begin to show up two to four days after treatment, with the full effects usually appearing within two weeks. Dryness lasts four to 12 months on average, but some studies have found that it can last up to 14 months.

Various studies have demonstrated its efficacy in reducing anxiety as well. For instance, according to a study published in the journal Scientific Reports in 2021, people who received Botox injections at four different sites reported significantly fewer signs of anxiety than those who received different treatments for the same conditions. The risk of anxiety was found to be reduced by 22.0% to 72.0% in Botox patients. Hence, the effectiveness of botulinum toxin type A in treating hyperhidrosis and its long-lasting effect is driving the market's growth.

North America is Expected to Hold the Largest Market Share Over the Forecast Period

North America is expected to dominate the overall hyperhidrosis treatment market throughout the forecast period. The growth is owing to factors such as the increasing burden of primary hyperhidrosis, cancer, and cardiovascular disorders, increases in secondary hyperhidrosis, technological advancements, and the presence of key market players in the region.

The high prevalence of primary and secondary hyperhidrosis will increase the adoption of treatment in the region. According to the NCBI research paper published in October 2022, approximately 2.8% of the US population suffers from hyperhidrosis, which is common in patients between 20 to 60 years of age. The high prevalence has increased the adoption of various treatments, such as over-the-counter aluminum chloride hexahydrate 20.0% in the region. Such prevalence will increase the demand for product consumption, thereby increasing the market's growth.

Key product launches, high concentration of market players or manufacturer's presence, acquisition and partnerships among major players, and increasing research and development activities for hyperhidrosis treatment products in the United States will lead to higher adoption of these products. For instance, in April 2021, Fortress Biotech, a partner company of Journey Medicals, entered into a definitive agreement to acquire Qbrexza (glycopyrronium) in the United States from Dermira, a wholly-owned subsidiary of Eli Lilly. Thus, owing to the above-mentioned factors, the market is expected to witness considerable growth over the forecast period.

Hyperhidrosis Treatment Market Competitor Analysis

The hyperhidrosis treatment market is moderately competitive and consists of several major players. The prominent players in the market are AbbVie, Brickell Biotech, Eli Lilly and Company (Dermira), Advin Healthcare, and Dermavant Scienecs Inc. (Roivant Sci), among others. The companies operating in the market are focusing on R&D investments and fundraising activities to conduct clinical trials that lead to strong product pipelines.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Product Code: 67388



  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Prevalence of Secondary Hyperhidrosis Condition
    • 4.2.2 Increase in Investments by Market Players in Research and Development
  • 4.3 Market Restraints
    • 4.3.1 Short-term Results of Cosmetic and Therapeutic Procedures
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Treatment Type
    • 5.1.1 Topical Treatments
    • 5.1.2 Surgical Treatments
    • 5.1.3 Botulin toxin A
    • 5.1.4 Iontophoresis
    • 5.1.5 Laser Treatments
    • 5.1.6 Other Treatment Types
  • 5.2 By Disease Type
    • 5.2.1 Primary Focal Hyperhidrosis
    • 5.2.2 Secondary Generalized Hyperhidrosis
  • 5.3 Geography
    • 5.3.1 North America
      • United States
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle East
      • GCC
      • South Africa
      • Rest of Middle East
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 AbbVie Inc. (Allergan PLC)
    • 6.1.2 Brickell Biotech Inc.
    • 6.1.3 Eli Lilly and Company (Dermira)
    • 6.1.4 1315 Capital (miraDry Inc.)
    • 6.1.5 SweatBlock
    • 6.1.6 Merz Pharma (Merz Aesthetics)
    • 6.1.7 Dermavant Sciences Inc. (Roivant Sciences)
    • 6.1.8 Advin Health Care
    • 6.1.9 Dermadry Laboratories Inc.
    • 6.1.10 Dermata Therapeutics Inc.


Have a question?

Jeroen Van Heghe

Manager - EMEA



Christine Sirois

Manager - Americas


Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!